Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 3
2006 2
2007 3
2008 2
2009 3
2010 3
2011 8
2012 8
2013 4
2014 9
2015 3
2016 6
2017 13
2018 8
2019 12
2020 10
2021 23
2022 20
2023 21
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

149 results

Results by year

Filters applied: . Clear all
Page 1
Experimental Models to Study Immune Dysfunction in the Pathogenesis of Parkinson's Disease.
Saponjic J, Mejías R, Nikolovski N, Dragic M, Canak A, Papoutsopoulou S, Gürsoy-Özdemir Y, Fladmark KE, Ntavaroukas P, Bayar Muluk N, Zeljkovic Jovanovic M, Fontán-Lozano Á, Comi C, Marino F. Saponjic J, et al. Among authors: comi c. Int J Mol Sci. 2024 Apr 14;25(8):4330. doi: 10.3390/ijms25084330. Int J Mol Sci. 2024. PMID: 38673915 Free PMC article. Review.
Shared and Unique Disease Pathways in Amyotrophic Lateral Sclerosis and Parkinson's Disease Unveiled in Peripheral Blood Mononuclear Cells.
Lualdi M, Casale F, Rizzone MG, Zibetti M, Monti C, Colugnat I, Calvo A, De Marco G, Moglia C, Fuda G, Comi C, Chiò A, Lopiano L, Fasano M, Alberio T. Lualdi M, et al. Among authors: comi c. ACS Chem Neurosci. 2023 Dec 6;14(23):4240-4251. doi: 10.1021/acschemneuro.3c00629. Epub 2023 Nov 8. ACS Chem Neurosci. 2023. PMID: 37939393 Free PMC article.
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY).
Chisari CG, Bianco A, Brescia Morra V, Calabrese M, Capone F, Cavalla P, Chiavazza C, Comi C, Danni M, Filippi M, Iaffaldano P, Lanzillo R, Lo Fermo S, Lucisano A, Lugaresi A, Lus G, Marfia GA, Marinelli F, Mirabella M, Moiola L, Perin C, Realmuto S, Toscano S, Trojano M, Vecchio D, Patti F; Italian MS Registry. Chisari CG, et al. Among authors: comi c. Neurotherapeutics. 2023 Oct;20(6):1696-1706. doi: 10.1007/s13311-023-01415-y. Epub 2023 Aug 23. Neurotherapeutics. 2023. PMID: 37610702 Free PMC article.
Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study.
Amato MP, Bergamaschi R, Centonze D, Mirabella M, Marfia GA, Totaro R, Lus G, Brescia Morra V, Aguglia U, Comi C, Cavalla P, Zaffaroni M, Rovaris M, Grimaldi LM, Leoni S, Malucchi S, Baldi E, Romano M, Falcini M, Perini P, Assetta M, Portaccio E, Sommacal S, Olivieri N, Parodi F, Todaro DS, Grassivaro N, Farina A, Mondino MM, Filippi M, Trojano M. Amato MP, et al. Among authors: comi c. J Neurol. 2023 Oct;270(10):4687-4696. doi: 10.1007/s00415-023-11820-0. Epub 2023 Jul 5. J Neurol. 2023. PMID: 37405689 Free PMC article.
149 results